Brief: Avadel Pharmaceuticals Q3 EPS USD 0
04/11/2025 21:01
Nov 04 (Reuters) - Avadel Pharmaceuticals Q3 net income USD 20 thousand vs. IBES estimate USD 7.71 million. Q3 operating expenses USD 79.646 million Q3 basic EPS USD 0 Q3 operating income USD 1.937 million vs. IBES estimate USD 9.29 million Q3 pretax profit USD 54 thousand vs. IBES estimate USD 6.57 million Q3 net product revenue USD 77.467 million
Recent news on Avadel Pharmaceuticals
See all newsBrief: Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 08:10 AM
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet